000153915 001__ 153915
000153915 005__ 20240229123053.0
000153915 0247_ $$2doi$$a10.1111/ejh.13409
000153915 0247_ $$2pmid$$apmid:32155662
000153915 0247_ $$2ISSN$$a0036-553X
000153915 0247_ $$2ISSN$$a0902-4441
000153915 0247_ $$2ISSN$$a1600-0609
000153915 0247_ $$2altmetric$$aaltmetric:77332888
000153915 037__ $$aDKFZ-2020-00525
000153915 041__ $$aeng
000153915 082__ $$a610
000153915 1001_ $$aKnauf, Wolfgang$$b0
000153915 245__ $$aFirst-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) - A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients.
000153915 260__ $$aOxford$$bWiley-Blackwell$$c2020
000153915 3367_ $$2DRIVER$$aarticle
000153915 3367_ $$2DataCite$$aOutput Types/Journal article
000153915 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1598860541_25230
000153915 3367_ $$2BibTeX$$aARTICLE
000153915 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153915 3367_ $$00$$2EndNote$$aJournal Article
000153915 500__ $$a2020 Aug;105(2):116-125
000153915 520__ $$aThe German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the 3-drug-combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM).Elderly MM patients requiring first-line therapy and not eligible for intensive treatment were enrolled in this phase IIb multicenter study. Patients were treated with BPV regimen for a maximum of 9 cycles.46 patients were included into the trial with a median age of 76 years. 19 patients had renal impairment at baseline. The ORR was 76.5%, the median progression free survival 25 months and overall survival at 24 month 83.3%. The clinical benefit rate (CBR) including MR was 91.2%. In patients with renal impairment at baseline a renal response was observed in 11 pts. with complete recovery of the renal function in 6 patients. The most frequent CTC grade 3/4 AEs experienced by patients were hematological (17.5%) and infectious (9.8%) complications. No new safety signals were observed for the study drugs under investigation.BPV may serve as a first-line regimen for transplant ineligible elderly MM patients in particular for patients with renal impairment requiring a fast and durable renal response.
000153915 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153915 588__ $$aDataset connected to CrossRef, PubMed,
000153915 7001_ $$aDingeldein, Gerrit$$b1
000153915 7001_ $$aSchlag, Rudolf$$b2
000153915 7001_ $$aWelslau, Manfred$$b3
000153915 7001_ $$00000-0003-1495-8917$$aMoehler, Thomas$$b4
000153915 7001_ $$0P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e$$aTerzer, Tobias$$b5
000153915 7001_ $$aWalter, Sarah$$b6
000153915 7001_ $$aGoldschmidt, Hartmut$$b7
000153915 7001_ $$aRaab, Marc-Steffen$$b8
000153915 7001_ $$0P:(DE-HGF)0$$agroup, BPV trial$$b9
000153915 773__ $$0PERI:(DE-600)2027114-1$$a10.1111/ejh.13409$$gp. ejh.13409$$n2$$p116-125$$tEuropean journal of haematology$$v105$$x1600-0609$$y2020
000153915 909CO $$ooai:inrepo02.dkfz.de:153915$$pVDB
000153915 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000153915 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153915 9141_ $$y2020
000153915 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J HAEMATOL : 2017
000153915 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153915 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153915 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153915 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153915 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153915 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153915 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000153915 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153915 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153915 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000153915 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000153915 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153915 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153915 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000153915 980__ $$ajournal
000153915 980__ $$aVDB
000153915 980__ $$aI:(DE-He78)C060-20160331
000153915 980__ $$aUNRESTRICTED